Halt Medical, Inc. announced today initial commercialization results for the Acessa System and additional launch plans.
"We are grateful and encouraged that virtually all our clinical trial sites expressed an interest in launching the Acessa Procedure. As of this past week, all four of our initial launch sites have purchased and performed procedures," said Jeffrey M. Cohen , Halt Medical CEO. He added, "This is testimony to the proven value of the Acessa Procedure in resolving the debilitating symptoms suffered by uterine fibroid patients."
The Acessa System was launched initially with the following physicians: Jay M. Berman , M.D., DMC Sinai-Grace Hospital, Detroit, MI; Scott G. Chudnoff , M.D., M.S., Montefiore Medical Center, New York, NY; Richard S. Guido , M.D., Magee-Womens Hospital of UPMC, Pittsburgh, PA; and David J. Levine , M.D., Mercy Hospital, Saint Louis, MO.
"The economic challenges to launching new technology in today's healthcare environment are daunting," said Rodney Marcy , Halt's Senior Vice President of Sales and Marketing. "Despite those challenges, our backlog of physicians and facilities desiring to integrate Acessa in to their procedural offering for the treatment of fibroids continues to grow. Current plans have us opening an additional five cities in April."
The Acessa™ System is a minimally invasive laparoscopic procedure that delivers radiofrequency energy to destroy the fibroids. After treatment, the fibroid is re-absorbed by the surrounding tissue. Acessa allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities. Nearly 300 women have been successfully treated with Acessa.
NCCN leaders collaborate to enhance cancer care in Vietnam